{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:58:43Z","timestamp":1790866723179,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.medine.2026.502518","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:40:22Z","timestamp":1788964822000},"page":"502518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in the critically ill cancer patient: What the intensivist should know"],"prefix":"10.1016","volume":"50","author":[{"given":"Mar\u00eda Ver\u00f3nica","family":"Nievas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Garc\u00eda-Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricela","family":"Jim\u00e9nez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ndido","family":"D\u00edaz-Lagares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2026.502518_bib0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunoterapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502518_bib0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.medine.2026.502518_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2014.01.010","article-title":"Allogeneic transplantation as anticancer immunotherapy","volume":"27","author":"Parmar","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.medine.2026.502518_bib0020","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.medine.2026.502518_bib0025","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medine.2026.502518_bib0030","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medine.2026.502518_bib0035","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medine.2026.502518_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.medine.2026.502518_bib0050","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medine.2026.502518_bib0055","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/cam4.5067","article-title":"Immune checkpoint inhibitors as first line in advanced melanoma: evaluating progression-free survival based on reconstructed individual patient data","volume":"12","author":"Ossato","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.medine.2026.502518_bib0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medine.2026.502518_bib0065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2026.502518_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101306","article-title":"Advances in the critical care management for patients with hematological malignancies","volume":"74","author":"Azoulay","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.medine.2026.502518_bib0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","article-title":"Critical care management of toxicities associated with targeted agents and immunotherapies for cancer","volume":"48","author":"Gutierrez","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medine.2026.502518_bib0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccc.2021.03.004","article-title":"Toxicity of immunotherapeutic agents","volume":"37","author":"Gutierrez","year":"2021","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.medine.2026.502518_bib0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.medine.2026.502518_bib0095","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-025-08155-x","article-title":"Life-threatening immune-related adverse events in the intensive care unit: a narrative review","author":"Pichon","year":"2025","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medine.2026.502518_bib0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.medine.2026.502518_bib0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25459","article-title":"Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the anti-PD-1Era","volume":"5","author":"Lamba","year":"2022","journal-title":"Jama Netw Open"},{"key":"10.1016\/j.medine.2026.502518_bib0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.medine.2026.502518_bib0115","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.medine.2026.502518_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0135","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.2147\/CMAR.S218756","article-title":"Management of immune checkpoint inhibitor toxicities","volume":"12","author":"Durrechou","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.medine.2026.502518_bib0140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14740338.2023.2254218","article-title":"Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies","volume":"22","author":"Turker","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.medine.2026.502518_bib0145","first-page":"7","article-title":"What should Intensivist know about immune checkpoint inhibitors and their side effects?","volume":"49","author":"Zlakov Aleksandrov","year":"2025","journal-title":"Med Intensiva"},{"key":"10.1016\/j.medine.2026.502518_bib0150","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy \u2013 induced overlap syndrome: myositis, myasthenia gravis, and myocarditis- a case series","author":"Aggarwal","year":"2024","journal-title":"Case Rep Med"},{"key":"10.1016\/j.medine.2026.502518_bib0155","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medine.2026.502518_bib0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502518_bib0165","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.medine.2026.502518_bib0170","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T- cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.medine.2026.502518_bib0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Sem Immunopathol"},{"key":"10.1016\/j.medine.2026.502518_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2023.05.009","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","author":"Wala","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.medine.2026.502518_bib0185","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR-T cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medine.2026.502518_bib0190","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medine.2026.502518_bib0195","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.medine.2026.502518_bib0200","article-title":"S\u00edndrome de liberaci\u00f3n de citoquina y s\u00edndrome hemofagoc\u00edtico asociados a inmunoterapia: una revisi\u00f3n narrativa","author":"Mayor-Vazquez","year":"2025","journal-title":"Med Intensiva"},{"key":"10.1016\/j.medine.2026.502518_bib0205","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.medin.2019.01.009","article-title":"Cytokine release syndrome. Reviewing a new entity in the intensive care unit","volume":"43","author":"Garc\u00eda-Roche","year":"2019","journal-title":"Med Intensiva"},{"key":"10.1016\/j.medine.2026.502518_bib0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medine.2026.502518_bib0215","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids of efficacy of chimeric antigen receptor T- cell therapy in large B-cell Lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medine.2026.502518_bib0220","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD 19 CAR-T cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gadner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.medine.2026.502518_bib0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell- associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy","volume":"430","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.medine.2026.502518_bib0230","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T- cell therapy-related CRS and ICANs: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.medine.2026.502518_bib0235","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T-cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.medine.2026.502518_bib0240","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medine.2026.502518_bib0245","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/jcm14051451","article-title":"Immunoeffector-cell-associated neurotoxicity syndrome After CAR-T therapy and other psychiatric manifestations: a review and case series","volume":"14","author":"Biciuc","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.medine.2026.502518_bib0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.medine.2026.502518_bib0255","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Heamatol"},{"key":"10.1016\/j.medine.2026.502518_bib0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0265","first-page":"2443","article-title":"How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medine.2026.502518_bib0270","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medine.2026.502518_bib0275","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T- cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medine.2026.502518_bib0280","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-021-00474-4","article-title":"Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer","volume":"18","author":"Ragoonanan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.medine.2026.502518_bib0285","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medine.2026.502518_bib0290","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR-T cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.medine.2026.502518_bib0295","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-Hematotox risk-stratifies patients for severe infections and disease progression after CD19 CAR T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0300","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.medine.2026.502518_bib0305","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.medine.2026.502518_bib0310","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0315","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medine.2026.502518_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102889","article-title":"Diagnosis and management of bispecific T cell-engaging antibody toxicity: a primer for emergency physicians","volume":"134","author":"Wattana","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.medine.2026.502518_bib0325","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231204198","article-title":"Current situation and prospect of adoptive cellular immunotherapy for malignancies","author":"Zhao","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.medine.2026.502518_bib0330","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PPO.0000000000000608","article-title":"Surgical considerations for tumor tissue procurement to obtain tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"28","author":"Mullinax","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.medine.2026.502518_bib0335","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.medine.2026.502518_bib0340","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.medine.2026.502518_bib0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102383","article-title":"Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned","volume":"9","author":"Borgers","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.medine.2026.502518_bib0350","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.medine.2026.502518_bib0355","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Warner","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0360","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) \u2013 expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medine.2026.502518_bib0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","article-title":"Glucocorticoids in T cell apoptosis and function","volume":"63","author":"Herold","year":"2006","journal-title":"Cel Mol LIfe Sci"},{"key":"10.1016\/j.medine.2026.502518_bib0370","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: Cardiooncology Primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.medine.2026.502518_bib0375","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1080\/1547691X.2024.2369123","article-title":"Analyzing IL-2-induced vascular leakage with an irAOP as tool","volume":"21","author":"Gogesch","year":"2024","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.medine.2026.502518_bib0380","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease-biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medine.2026.502518_bib0385","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medine.2026.502518_bib0390","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41409-021-01403-w","article-title":"Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis","volume":"56","author":"Abboud","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.medine.2026.502518_bib0395","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572726001761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572726001761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:35:00Z","timestamp":1790865300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572726001761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2173572726001761"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2026.502518","relation":{},"ISSN":["2173-5727"],"issn-type":[{"value":"2173-5727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in the critically ill cancer patient: What the intensivist should know","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2026.502518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2026.502518","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. and SEMICYUC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502518"}}